Aumento Capital V Corporation

Completion of Special Meeting of Shareholders

TORONTO, ONTARIO--(Marketwired - Jan. 23, 2017) - Aumento Capital V Corporation (TSX VENTURE:AWN.P) ("Aumento" or the "Corporation") is pleased to announce that all of the resolutions considered at today's special meeting of shareholders (the "Shareholders Meeting") were approved by shareholders of the Corporation ("Shareholders").

Amongst other things, the Shareholders approved a resolution to set the number of directors of Corporation at six, an increase from the current number of three and the appointment of Josh Arbuckle, Ryan Hunter and Graeme Norwood as the additional directors of the Corporation, each of whom immediately resigned following Shareholders Meeting. The expansion of the Board was done to accommodate the appointment of a Board of six members who are anticipated to be appointed upon completion of the closing of the Corporation's previously announced qualifying transaction (the "Transaction") with WeedMD RX Inc. ("WMD").

The current Board remains comprised of Roger Daher, David Danziger and Paul Pathak, who will all remain on the Board until completion of the Transaction.

About WeedMD RX Inc.

WeedMD is a licensed producer of medical cannabis pursuant to the Access to Cannabis for Medical Purposes Regulations (ACMPR). WeedMD operates a 25,000 square foot, scalable production facility in Aylmer, Ontario with four acres of property for future expansion. The Company is focused on providing consistent, quality medicine to the long-term care and assisted living markets in Canada through its comprehensive platform developed exclusively for that industry. WeedMD is dedicated to educating healthcare practitioners and furthering public understanding of the role medical cannabis can play as a viable alternative to prescription medication in relieving a variety of chronic medical conditions and illnesses.

Aumento will issue additional press releases related to the final legal structure of the Transaction, officers and directors of the resulting issuer, sponsorship and other material information as it becomes available. For further information regarding the Transaction, please contact:

David Danziger, CEO

[e-mail]

[phone]

Completion of the Transaction is subject to a number of conditions, including but not limited to, TSXV acceptance and, if applicable, pursuant to the requirements of the TSXV, majority of the minority shareholder approval. Where applicable, the transaction cannot close until the required shareholder approval is obtained. There can be no assurance that the transaction will be completed as proposed or at all.